Poxel reports revenue for the second quarter and first half of 2024 and provides company update Page 1

Regulatory news:

POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its revenue for the second quarter and first half of 2024.

Thomas Kuhn, CEO of Poxel, stated: “As our exclusive discussions on monetizing royalties from the sale of TWYMEEG in Japan come to a close, the topline results recently received from our partner Sumitomo Pharma from the post-marketing TWINKLE clinical trial confirm the product’s profile for type 2 diabetics with renal impairment. These results provide a basis for our partner to begin discussions with regulators in Japan regarding the revision of the TWYMEEG package insert and the appropriateness of recommending TWYMEEG. to Japanese type 2 diabetics with renal impairment.”